Switch theme
Sign up to access all valuation multiples
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
2018
427
LTM Revenue $116M
LTM EBITDA -$202M
$599M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Phathom Pharmaceuticals has a last 12-month revenue (LTM) of $116M and a last 12-month EBITDA of -$202M.
In the most recent fiscal year, Phathom Pharmaceuticals achieved revenue of $55.3M and an EBITDA of -$262M.
Phathom Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Phathom Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $116M | XXX | $55.3M | XXX | XXX | XXX |
| Gross Profit | $98.9M | XXX | $47.3M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | -$202M | XXX | -$262M | XXX | XXX | XXX |
| EBITDA Margin | -174% | XXX | -473% | XXX | XXX | XXX |
| EBIT | -$221M | XXX | -$277M | XXX | XXX | XXX |
| EBIT Margin | -191% | XXX | -502% | XXX | XXX | XXX |
| Net Profit | -$280M | XXX | -$334M | XXX | XXX | XXX |
| Net Margin | -242% | XXX | -605% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Phathom Pharmaceuticals's stock price is $9.
Phathom Pharmaceuticals has current market cap of $608M, and EV of $599M.
See Phathom Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $599M | $608M | XXX | XXX | XXX | XXX | $-4.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Phathom Pharmaceuticals has market cap of $608M and EV of $599M.
Phathom Pharmaceuticals's trades at 10.8x EV/Revenue multiple, and -2.3x EV/EBITDA.
Equity research analysts estimate Phathom Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Phathom Pharmaceuticals has a P/E ratio of -2.2x.
See valuation multiples for Phathom Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $608M | XXX | $608M | XXX | XXX | XXX |
| EV (current) | $599M | XXX | $599M | XXX | XXX | XXX |
| EV/Revenue | 5.2x | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBITDA | -3.0x | XXX | -2.3x | XXX | XXX | XXX |
| EV/EBIT | -2.7x | XXX | -2.2x | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.2x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | -2.3x | XXX | -2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPhathom Pharmaceuticals's last 12 month revenue growth is 118%
Phathom Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.8M for the same period.
Phathom Pharmaceuticals's rule of 40 is -23203% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Phathom Pharmaceuticals's rule of X is 122% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Phathom Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 118% | XXX | 141% | XXX | XXX | XXX |
| EBITDA Margin | -174% | XXX | -473% | XXX | XXX | XXX |
| EBITDA Growth | -77% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -23203% | XXX | -355% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 122% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 588% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Phathom Pharmaceuticals acquired XXX companies to date.
Last acquisition by Phathom Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Phathom Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Phathom Pharmaceuticals founded? | Phathom Pharmaceuticals was founded in 2018. |
| Where is Phathom Pharmaceuticals headquartered? | Phathom Pharmaceuticals is headquartered in United States of America. |
| How many employees does Phathom Pharmaceuticals have? | As of today, Phathom Pharmaceuticals has 427 employees. |
| Who is the CEO of Phathom Pharmaceuticals? | Phathom Pharmaceuticals's CEO is Mr. Steven L. Basta. |
| Is Phathom Pharmaceuticals publicy listed? | Yes, Phathom Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Phathom Pharmaceuticals? | Phathom Pharmaceuticals trades under PHAT ticker. |
| When did Phathom Pharmaceuticals go public? | Phathom Pharmaceuticals went public in 2019. |
| Who are competitors of Phathom Pharmaceuticals? | Similar companies to Phathom Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Phathom Pharmaceuticals? | Phathom Pharmaceuticals's current market cap is $608M |
| What is the current revenue of Phathom Pharmaceuticals? | Phathom Pharmaceuticals's last 12 months revenue is $116M. |
| What is the current revenue growth of Phathom Pharmaceuticals? | Phathom Pharmaceuticals revenue growth (NTM/LTM) is 118%. |
| What is the current EV/Revenue multiple of Phathom Pharmaceuticals? | Current revenue multiple of Phathom Pharmaceuticals is 5.2x. |
| Is Phathom Pharmaceuticals profitable? | Yes, Phathom Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Phathom Pharmaceuticals? | Phathom Pharmaceuticals's last 12 months EBITDA is -$202M. |
| What is Phathom Pharmaceuticals's EBITDA margin? | Phathom Pharmaceuticals's last 12 months EBITDA margin is -174%. |
| What is the current EV/EBITDA multiple of Phathom Pharmaceuticals? | Current EBITDA multiple of Phathom Pharmaceuticals is -3.0x. |
| What is the current FCF of Phathom Pharmaceuticals? | Phathom Pharmaceuticals's last 12 months FCF is -$256M. |
| What is Phathom Pharmaceuticals's FCF margin? | Phathom Pharmaceuticals's last 12 months FCF margin is -221%. |
| What is the current EV/FCF multiple of Phathom Pharmaceuticals? | Current FCF multiple of Phathom Pharmaceuticals is -2.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
